Celldex Awaits Key Barzolvolimab Data as Pipeline Advances — Celldex Therapeutics, Inc.

Event summary

Barzolvolimab Phase 3 trials in chronic spontaneous urticaria completed enrollment six months ahead of schedule, with topline data expected September/October 2026.
CDX-622 bispecific antibody showed rapid, dose-dependent reductions in serum tryptase and was well-tolerated in Phase 1 trials.
Celldex reported $717.6 million in cash reserves as of June 30, 2026, up from $451.5 million three months prior.
Phase 2 prurigo nodularis study discontinued after failing to meet primary endpoints.

The big picture

Celldex is positioning itself as a leader in mast cell science, with barzolvolimab and CDX-622 targeting inflammatory diseases where mast cells are implicated. The company's focus on shifting treatment paradigms comes amid growing industry interest in novel antibody-based treatments for allergic and inflammatory disorders. With topline data imminent for its lead candidate, Celldex's strategic moves will be closely watched by investors and operators in the biotech space.

What we're watching

Regulatory Timeline: Whether the September/October topline data for barzolvolimab will support a 2027 BLA submission as planned.
Pipeline Diversification: How CDX-622's progress in asthma and potential expansion into allergic rhinitis and food allergy will impact Celldex's portfolio.
Financial Runway: The pace at which Celldex burns through its $717.6 million cash reserves given increased R&D and commercial planning expenses.